quisinostat + checkpoint inhibitors

Quisinostat is a potent, orally bioavailable second-generation histone deacetylase (HDAC) inhibitor with high selectivity for HDAC1. Originally developed by Janssen Pharmaceutica NV and licensed to NewVac LLC, quisinostat is being investigated in combination with various immune checkpoint inhibitors (targeting PD-1, PD-L1, and CTLA-4) to treat advanced solid tumors. The therapeutic rationale for this combination lies in the ability of HDAC inhibition to modulate the tumor microenvironment, increase the expression of tumor-associated antigens and MHC molecules, and reduce the presence of immunosuppressive cells, thereby enhancing the efficacy of immune checkpoint blockade. This combination strategy is currently in preclinical development for several indications, including metastatic non-small cell lung cancer (NSCLC), renal cell carcinoma, ovarian cancer, triple-negative breast cancer, and melanoma.

Other names

HDAC1 inhibitor + immune checkpoint blockadequisinostat + anti-PD-1quisinostat + anti-PD-L1quisinostat + anti-CTLA-4